Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC 50 s of 0.85 and 1.25 μM, respectively, and has antitumor and antiinflammatory activity.
Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PKC | Products > Signaling Pathways > Antibiotic
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.